Methods and formulations for treating female sexual dysfunction are provided. A pharmaceutical composition formulated so as to contain a selected vasoactive agent is administered to the vagina, vulvar area or urethra of the individual undergoing treatment. Suitable vasoactive agents are vasodilators, including naturally occurring prostaglandins, synthetic prostaglandin derivatives, endothelial-derived relaxation factors, vasoactive intestinal polypeptide agonists, smooth muscle relaxants, leukotriene inhibitors, and others. The formulations are also useful for preventing the occurrence of yeast infections, improving vaginal muscle tone and tissue health, enhancing vaginal lubrication, and minimizing excess collagen deposition. A clitoral drug delivery device is also provided.

Os métodos e os formulations para o dysfunction sexual fêmea de tratamento são fornecidos. Uma composição pharmaceutical formulada para conter um agente vasoactive selecionado é administrado ao vagina, à área vulvar ou ao urethra do tratamento se submetendo individual. Os agentes vasoactive apropriados são vasodilators, including prostaglandins naturais, derivatives sintéticos do prostaglandin, fatores endothelial-derivados do relaxation, agonists intestinal vasoactive do polypeptide, relaxants lisos do músculo, inibidores do leukotriene, e outros. Os formulations são também úteis para impedir a ocorrência de infecções do fermento, melhorar o tom do músculo e a saúde vaginal do tecido, realçar a lubrificação vaginal, e minimizar o deposition adicional do collagen. Um dispositivo clitoral da entrega da droga é fornecido também.

 
Web www.patentalert.com

< Electrotransort device comprising blades

< Biomaterial derived from follicle basement membranes

> Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases

> 3-heterocyclylpropanohydroxamic acid PCP inhibitors

~ 00078